Business Insider
My Markets Watchlist
Markets Stocks

Mersana Therapeutics Inc Registered Shs Stock , MRSN

0.33 -0.03 -7.73%
03:59:59 PM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Thursday 06/26/2025 the closing price of the Mersana Therapeutics Inc Registered Shs share was $0.33 on BTT. Compared to the opening price on Thursday 06/26/2025 on BTT of $0.35, this is a drop of 6.17%. Mersana Therapeutics Inc Registered Shs's market capitalization is $35.02 M by 124.63 M shares outstanding.
Is Mersana Therapeutics stock a Buy, Sell or Hold? Mersana Therapeutics stock has received a consensus rating of hold. The average rating score is and is based on 4 buy ratings, 5 hold ratings, and 0 sell ratings.
What was the 52-week low for Mersana Therapeutics stock? The low in the last 52 weeks of Mersana Therapeutics stock was 0.26. According to the current price, Mersana Therapeutics is 125.27% away from the 52-week low.
What was the 52-week high for Mersana Therapeutics stock? The high in the last 52 weeks of Mersana Therapeutics stock was 2.83. According to the current price, Mersana Therapeutics is 11.53% away from the 52-week high.
What are analysts forecasts for Mersana Therapeutics stock? The 9 analysts offering price forecasts for Mersana Therapeutics have a median target of 4.22, with a high estimate of 7.00 and a low estimate of 1.00. The median estimate represents a 7.71 difference from the last price of 0.33.

Mersana Therapeutics Stock Snapshot

0.28
Bid
100.00
Bid Size
0.38
Ask
100.00
Ask Size
6/26/2025
Date
3:59 PM
Time
18,639.00
Volume
0.35
Prev. Close
0.35
Open
43.73 M
Market Cap in USD
124.63 M
Number of Shares
124.63 M
Total Number of Shares
0.32
Day Low
0.35
Day High
0.33
0.26
52 Week Low
2.83
52 Week High
0.33
0.00
Dividend in USD
0.00
Dividend Yield
77.70
Free Float in %
-0.56
EPS in USD
-0.08
Book Value per Share in USD
-0.67
Cash Flow per Share in USD

Historical Prices for Mersana Therapeutics

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Mersana Therapeutics Analyst Data

Total Analysts: 9
Buy Ratings: 4 Neutral Ratings: 5 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 1.00 Median: 4.22 Highest: 7.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Mersana Therapeutics Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/16/25 Guggenheim
Maintained Buy $5
02/06/25 William Blair
Maintained Buy
03/19/24 J.P. Morgan
Upgraded to Hold $5
02/29/24 Wedbush Morgan Securities Inc.
Upgraded to Buy $7
02/29/24 Baird Patrick & Co
Maintained Hold $5
02/29/24 Guggenheim
Upgraded to Buy $7
12/04/23 Citigroup Corp.
Upgraded to Buy $5
07/28/23 Citigroup Corp.
Downgraded to Hold $1
07/28/23 Baird Patrick & Co
Downgraded to Hold $1
07/27/23 Wedbush Morgan Securities Inc.
Downgraded to Hold $2

Mersana Therapeutics Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 23 23 14 122 477
Dividend - - - - -
Dividend Yield (in %) 0.00 % 0.00 % - - -
EPS -0.60 -0.58 -0.72 -0.18 1.55
P/E Ratio -0.54 -0.56 -0.45 -1.81 0.21
EBIT -80 -89 -114 -44 261
EBITDA - - - - -
Net Profit -80 -88 -113 -43 250
Net Profit Adjusted - - - - -
Pre-Tax Profit -80 -88 -113 -43 261
Pre-Tax Profit Reported - - - - -
EPS (Non-GAAP) ex. SOE -0.59 -0.43 -0.41 -0.47 -
EPS (GAAP) -0.59 -0.52 -0.52 0.13 1.55
Gross Income - - - - -
Cash Flow from Investing 25 -1 -1 -16 -19
Cash Flow from Operations -76 -71 -84 -16 235
Cash Flow from Financing 98 90 - - -
Cash Flow per Share - - - - -
Free Cash Flow - - - - -
Free Cash Flow per Share - - - - -
Book Value per Share - - - - -
Net Debt - - - - -
Research & Development Exp. 68 75 85 93 90
Capital Expenditure 2 1 1 16 19
Selling, General & Admin. Exp. 34 37 46 53 -
Shareholder’s Equity 32 -38 -115 28 295
Total Assets 178 108 32 184 453
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 7 7 7 7
Average Estimate - -0.157 USD -0.143 USD -0.599 USD -0.584 USD
Year Ago - -0.198 USD -0.094 USD -0.565 USD -
Publish Date - 8/6/2025 11/11/2025 - -
Revenue Estimates
No. of Analysts - 7 7 7 7
Average Estimate - 6 USD 6 USD 23 USD 23 USD
Year Ago - 2 USD 13 USD 40 USD -
Publish Date - 8/6/2025 11/11/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 40.50 36.86 26.58 0.04 0.83 42.12 10.59
Change of sales in % 9.88 38.65 61,716.28 -94.81 -98.03 297.61 -39.62
Gross profit on sales 38.87 35.34 25.65 - - - -
Gross profit on sales change in % 9.99 37.75 - - - - -
Operating income -73.34 -170.96 -203.77 -168.86 -88.11 -30.20 -65.66
Operating income change in % 57.10 16.10 -20.67 -91.64 -191.75 54.00 -65.72
Income before tax -68.77 -171.67 -204.21 -170.06 -88.05 -28.21 -64.26
Income before tax change in % 59.94 15.94 -20.08 -93.15 -212.13 56.10 -66.01
Income after tax -69.19 -171.67 -204.21 -170.06 -88.05 -28.21 -64.26
Income after tax change in % 59.69 15.94 -20.08 -93.15 -212.13 56.10 -66.01

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 154.17 189.16 242.28 84.37 45.31 29.22 69.71
Long-term liabilities per share 0.79 1.04 1.43 0.50 - - 0.01
Equity -9.51 36.90 92.06 121.74 228.09 78.32 8.80
Equity change in % -125.77 -59.91 -24.38 -46.63 191.23 790.48 -87.43
Balance sheet total 144.66 226.06 334.34 206.11 273.40 107.54 78.50
Balance sheet total change in % -36.01 -32.39 62.21 -24.61 154.23 36.99 -39.94

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 0.33 0.32 0.28 0.00 0.01 0.97 0.46
P/E ratio (year end quote, basic EPS) - - - - - - -
P/E ratio (year end quote, diluted EPS) - - - - - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % -6.57 16.32 27.53 59.07 83.43 72.83 11.20
Debt ratio in % 106.57 83.68 72.47 40.93 16.57 27.17 88.80

Mersana Therapeutics Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Huber Martin H. Jr. 01/15/2025 4,514.00 122,875.00 0.58 Sell No
Bala Mohan 01/15/2025 5,939.00 68,872.00 0.58 Sell No
Carvajal Alejandra 01/15/2025 5,096.00 78,296.00 0.58 Sell No
DeSchuytner Brian 01/15/2025 8,470.00 121,393.00 0.58 Sell No
DeSchuytner Brian 01/14/2025 2,331.00 109,030.00 0.63 Sell No
Lowinger Timothy B 01/14/2025 1,794.00 245,930.00 0.63 Sell No
Protopapas Anna 01/14/2025 6,191.00 155,428.00 0.63 Sell No
Mandelia Ashish 01/14/2025 1,791.00 52,388.00 0.63 Sell No
Carvajal Alejandra 01/14/2025 952.00 70,892.00 0.63 Sell No
Bala Mohan 01/14/2025 14,583.00 74,811.00 n/a Buy No
Huber Martin H. Jr. 01/14/2025 11,062.00 127,389.00 n/a Buy No
DeSchuytner Brian 01/14/2025 6,250.00 115,280.00 n/a Buy No
DeSchuytner Brian 01/14/2025 14,583.00 129,863.00 n/a Buy No
Carvajal Alejandra 01/14/2025 12,500.00 83,392.00 n/a Buy No
Mandelia Ashish 01/13/2025 1,007.00 49,396.00 0.66 Sell No
Protopapas Anna 01/13/2025 11,534.00 144,869.00 0.66 Sell No
DeSchuytner Brian 01/13/2025 3,713.00 105,111.00 0.66 Sell No
Lowinger Timothy B 01/13/2025 3,483.00 242,932.00 0.66 Sell No
Carvajal Alejandra 01/13/2025 3,330.00 69,344.00 0.66 Sell No
Bala Mohan 01/13/2025 3,253.00 60,228.00 0.66 Sell No
DeSchuytner Brian 01/13/2025 6,250.00 111,361.00 n/a Buy No
Protopapas Anna 01/13/2025 16,750.00 161,619.00 n/a Buy No
Lowinger Timothy B 01/13/2025 4,792.00 247,724.00 n/a Buy No
Mandelia Ashish 01/13/2025 4,783.00 54,179.00 n/a Buy No
Carvajal Alejandra 01/13/2025 2,500.00 71,844.00 n/a Buy No

Mersana Therapeutics Dividend Calendar

Date Name Dividend *yield Currency
2024 Mersana Therapeutics Inc Registered Shs 0.00 0.00 USD
2023 Mersana Therapeutics Inc Registered Shs 0.00 0.00 USD
2022 Mersana Therapeutics Inc Registered Shs 0.00 0.00 USD
2021 Mersana Therapeutics Inc Registered Shs 0.00 0.00 USD
2020 Mersana Therapeutics Inc Registered Shs 0.00 0.00 USD
2019 Mersana Therapeutics Inc Registered Shs 0.00 0.00 USD
2018 Mersana Therapeutics Inc Registered Shs 0.00 0.00 USD
2017 Mersana Therapeutics Inc Registered Shs 0.00 0.00 USD
2016 Mersana Therapeutics Inc Registered Shs - - USD
2015 Mersana Therapeutics Inc Registered Shs - - USD
*Yield of the Respective Date

Mersana Therapeutics Calendar

Event Estimate Info Date
Earnings Report -0.157 USD Q2 2025 Earnings Release 08/06/2025
Earnings Report -0.143 USD Q3 2025 Earnings Release 11/11/2025
Earnings Report -0.131 USD Q4 2025 Earnings Release 03/04/2026
Earnings Report -0.189 USD Q1 2026 Earnings Release 05/11/2026

Mersana Therapeutics Past Events

Event Actual EPS Info Date
Annual General Meeting -0.560 USD Annual General Meeting 06/12/2025
Earnings Report -0.190 USD Q1 2025 Earnings Release 05/15/2025
Earnings Report -0.110 USD Q4 2024 Earnings Release 03/03/2025
Earnings Report -0.090 USD Q3 2024 Earnings Release 11/13/2024
Earnings Report -0.200 USD Q2 2024 Earnings Release 08/13/2024
Annual General Meeting -1.480 USD Annual General Meeting 06/11/2024
Earnings Report -0.160 USD Q1 2024 Earnings Release 05/09/2024
Earnings Report -0.160 USD Q4 2023 Earnings Release 02/28/2024
Earnings Report -0.350 USD Q3 2023 Earnings Release 11/07/2023
Earnings Report -0.470 USD Q2 2023 Earnings Release 08/08/2023
Annual General Meeting -2.180 USD Annual General Meeting 06/08/2023
Earnings Report -0.520 USD Q1 2023 Earnings Release 05/09/2023
Earnings Report -0.440 USD Q4 2022 Earnings Release 02/28/2023
Earnings Report -0.610 USD Q3 2022 Earnings Release 11/07/2022
Earnings Report -0.550 USD Q2 2022 Earnings Release 08/08/2022
Annual General Meeting -2.410 USD Annual General Meeting 06/09/2022
Earnings Report -0.590 USD Q1 2022 Earnings Release 05/09/2022
Earnings Report -0.680 USD Q4 2021 Earnings Release 02/28/2022

Mersana Therapeutics Profile

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
8
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
OSZAR »